Acadia Pharmaceuticals Inc. (NasdaqGS: ACAD)
Health Care · Biotechnology · US
$19.85
+0.35% today · -4.1% 1Y
Acadia Pharmaceuticals Inc. (NasdaqGS: ACAD) operates in the Biotechnology industry within the Health Care sector. The company is valued at $3.41B and employs 797 people.
Over the last twelve months the share price has lost 4.1%, trading between 19.46 and 30.96.
Tweenvest scores Acadia Pharmaceuticals Inc. across four factors: quality 71/100, value 59/100, growth 96/100. Its strongest factor is growth.
ACAD price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.41B
- Revenue (TTM)
- $1.14B
- P/E
- 8.97
- EPS
- 2.21
- Dividend yield
- —
- Beta (5Y)
- 0.89
- 52-week high
- $30.96
- 52-week low
- $19.46
- Avg volume (3M)
- —
- Shares outstanding
- 172.31M
- Employees
- 797
- Next earnings
- —
About Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
- ISIN
- US0042251084
- Founded
- 1993
- Listed since
- May 27, 2004
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Shanghai Henlius Biotech, Inc.SEHK: 2696 | $3.53B | HK$50.75 | -13.10% |
| Walvax Biotechnology Co., Ltd.SZSE: 300142 | $3.52B | CN¥14.75 | +3.65% |
| IDEAYA Biosciences, Inc.NasdaqGS: IDYA | $3.48B | $36.11 | +0.14% |
| InnoCare Pharma LimitedSEHK: 9969 | $3.46B | HK$12.73 | -6.60% |
| Arcutis Biotherapeutics, Inc.NasdaqGS: ARQT | $3.34B | $26.25 | -1.24% |
| Viking Therapeutics, Inc.NasdaqCM: VKTX | $3.33B | $28.36 | -0.53% |
| Celcuity Inc.NasdaqCM: CELC | $3.32B | $68.00 | +0.09% |
| CareDx, Inc.NasdaqGM: CDNA | $3.29B | $63.60 | -0.11% |
Figures last refreshed Oct 11, 2026.